TENAX THERAPEUTICS, INC. — Share Issue/Capital Change 2021

Sep 2, 2021

S-8 1 tenx_s8.htm PRIMARY DOCUMENT Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2021 Issuer Direct Corporation tenx_s8

style header

As filed with the Securities and Exchange Commission on September 2, 2021

Registration No. 333-___

Rule Below Paragraph

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Rule Below Paragraph

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Rule Below Paragraph

TENAX THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Rule Below Paragraph

Delaware	26-2593535
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
ONE Copley Parkway, Suite 490 Morrisville, North Carolina	27560
(Address of Principal Executive Offices)	(Zip Code)

Tenax Therapeutics, Inc. 2016 Stock Incentive Plan

Plan for Employee Inducement Stock Option Grants

(Full title of the Plan)

Rule Below Paragraph

Michael B. Jebsen

President and Chief Financial Officer

Tenax Therapeutics, Inc.

ONE Copley Parkway, Suite 490

Morrisville, North Carolina 27560

(919) 855-2100

(Name, address and telephone number, including area code, of agent for service)

Copy to:

Margaret N. Rosenfeld, Esq.

K&L Gates LLP

4350 Lassiter at North Hills Avenue

Suite 300

Raleigh, North Carolina 27609

(919) 743-7351

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities
Act.			☐

page break line

Title of securities to be registered	Amount to be Registered	Proposed maximum offering price per share	Proposed maximum aggregate offering price	Amount of registration fee
Common
Stock, par value $0.0001 per share	750,000(1)	$1.605(2)	$1,203,750
(2)	$131.33
Common
Stock, par value $0.0001 per share	350,000 (3)	$1.605(2)	$561,750 (2)	$61.29
(1)	This Registration Statement registers 750,000 additional shares of
common stock, par value $0.0001 per share (“Common
Stock”), of Tenax Therapeutics, Inc. which are issuable under
the Tenax Therapeutics, Inc. 2016 Stock Incentive Plan. Pursuant to
Rule 416(a) under the Securities Act of 1933, as amended (the
“Securities Act”), this Registration Statement also
covers such additional shares of Common Stock as may be issued to
prevent dilution from stock splits, stock dividends and similar
transactions.
(2)	Pursuant to Rules 457(c) and 457(h)(1) under the Securities Act,
the proposed maximum offering price per share and the proposed
maximum aggregate offering price for the shares have been
calculated solely for the purpose of computing the registration fee
on the basis of the average of the high and low prices of the
Common Stock reported on the Nasdaq Capital Market on August 30,
2021.
(3)	This Registration Statement registers 350,000 shares of Common
Stock of Tenax Therapeutics, Inc. which are issuable under the Plan
for Employee Inducement Stock Option Grants. Pursuant to Rule
416(a) under the Securities Act of 1933, as amended (the
“Securities Act”), this Registration Statement also
covers such additional shares of Common Stock as may be issued to
prevent dilution from stock splits, stock dividends and similar
transactions.

style footer

page break line

EXPLANATORY NOTE

Tenax Therapeutics, Inc. (the “Registrant”) has filed this Registration Statement to register under the Securities Act of 1933, as amended (the “Securities Act”), the offer and sale of 750,000 additional shares of common stock of the Registrant, par value $0.0001 per share (the “Common Stock”), under the Tenax Therapeutics, Inc. 2016 Stock Incentive Plan (the “2016 Plan”, and such shares offered and sold under the 2016 Plan, the “2016 Plan Shares”), pursuant to a vote in favor of such offer and sale by the Shareholders of the Registrant on June 10, 2021, as filed with the Securities and Exchange Commission (the “Commission”) on June 11, 2021 . The 2016 Plan Shares are of the same class as other securities issuable pursuant to the 2016 Plan for which the Registrant’s Registration Statements on Form S-8 (Registration Nos. 333-224120 and 333-233571), filed with the Securities and Exchange Commission (the “Commission”) on April 3, 2018 and August 30, 2019 , respectively (the “Prior Registration Statements”), remains effective. The information contained in the Prior Registration Statements are hereby incorporated by reference pursuant to General Instruction E of Form S-8, except to the extent supplemented, amended or superseded by the information set forth in this Registration Statement.

The Registrant has additionally filed this Registration Statement to register under the Securities Act the offer and sale of 350,000 shares of Common Stock under the Plan for Employee Inducement Stock Option Grants (the “Inducement Plan”). On July 6, 2021, as disclosed in the Registrant’s Current Report filed with the Commission on July 8, 2021 , the Inducement Plan was approved by the Compensation Committee of the Board of Directors of the Registrant as a stock option plan solely for use in making employee inducement stock option grants to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

PART I

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 1. Plan Information.

The documents containing the information specified in this Item 1 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

Item 2. Registrant Information and Employee Plan Annual Information.

The documents containing the information specified in this Item 2 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

page break line

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference .

The following documents filed with the Commission are hereby incorporated by reference in this Registration Statement:

(a)

The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Commission on March 31, 2021 , as amended by the Registrant’s Amendment No. 1 to Annual Report filed with the Commission on April 16, 2021 ;

(b)

The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 30, 2021 ;

(c)

The Registrant’s Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2021, filed with the Commission on May 17, 2021 , and for the quarterly period ended June 30, 2021, filed with the Commission on August 16, 2021

(d)

The Registrant’s Current Reports on Form 8-K filed with the Commission on January 19, 2021 (as amended by Form 8-K/A filed with the SEC on March 30, 2021 ), March 2, 2021 , April 7, 2021 , June 1, 2021 , June 11, 2021 , and July 8, 2021 ; and

(e)

The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on January 11, 2010 , as updated by the description of the Registrant’s Common Stock included in Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Commission on March 31, 2021 , and any amendments or reports filed for the purpose of updating such description.

In addition, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. However, any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed “filed” with the Commission, including without limitation any information furnished pursuant to Item 2.02 or 7.01 of Form 8-K or certain exhibits furnished pursuant to Item 9.01 of Form 8-K, shall not be deemed to be incorporated by reference in this Registration Statement.

Any statement in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 4. Description of Securities.

Not applicable.

Item 5. Interests of Named Experts and Counsel.

Not applicable

Item 6. Indemnification of Directors and Officers.

Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against amounts paid and expenses incurred in connection with an action or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal proceeding, if such person had no reasonable cause to believe his or her conduct was unlawful. In the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any matter as to which such person has been adjudged to be liable to the corporation unless and only to the extent that the adjudicating court determines that such indemnification is proper under the circumstances.

page break line

Our Certificate of Incorporation and Bylaws provide that our directors and officers will be indemnified by us to the fullest extent authorized by the Delaware General Corporation Law. In addition, the Certificate of Incorporation provides, as permitted by Section 102(b)(7) of the Delaware General Corporation Law, that our directors will not be liable for monetary damages to us for breaches of their fiduciary duty as directors, unless they (i) violated their duty of loyalty to us or our stockholders, (ii) acted, or failed to act, in good faith, (iii) acted with intentional misconduct, (iv) knowingly or intentionally violated the law, (v) authorized unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or (vi) derived an improper personal benefit from their actions as directors.

Our Bylaws also permit us to secure insurance on behalf of any officer, director, employee, or agent for any liability arising out of his or her actions, regardless of whether Delaware General Corporation Law would permit indemnification. We have purchased a policy of directors’ and officers’ liability insurance that insures our directors and officers.

In addition, we have also entered into an indemnification agreement with certain of our directors and officers. The indemnification agreements require us to indemnify and hold harmless and advance expenses to each indemnitee in respect of acts or omissions occurring prior to the time the indemnitee ceases to be an officer and/or director of the Company to the fullest extent permitted by applicable law. The rights provided in the indemnification agreements are in addition to the rights provided in our Certificate of Incorporation, Bylaws, and the Delaware General Corporation Law.

Item 7. Exemption from Registration Claimed.

Not applicable.

Item 8. Exhibits.

The following exhibits have been or are being filed herewith and are numbered in accordance with Item 601 of Regulation S-K:

Exhibit No.	Description
3.1	Certificate
of Incorporation (incorporated by reference to Exhibit 3.1 to the
Registrant’s Current Report on Form 8-K filed with the
Commission on June 30, 2008).
3.2	Certificate
of Amendment of the Certificate of Incorporation ( incorporated by reference to Exhibit 3.1 to the
Registrant’s Current Report on Form 8-K filed with the
Commission on November 13, 2009).
3.3	Certificate
of Amendment of the Certificate of Incorporation ( incorporated by reference to Exhibit 3.1 to the
Registrant’s Current Report on Form 8-K filed with the
Commission on May 15, 2013).
3.4	Certificate
of Amendment of the Certificate of Incorporation ( incorporated by reference to Exhibit 3.4 to the
Registrant’s Quarterly Report on Form 10-Q filed with the
Commission on December 15, 2014 ).
3.5	Certificate
of Amendment of the Certificate of Incorporation (incorporated by
reference to Exhibit 3.5 to the Registrant’s Current Report
on Form 8-K filed with the Commission on February 23,
2018).
3.6	Certificate
of Designation of Series A Convertible Preferred Stock
( incorporated by reference to Exhibit
4.1 to the Registrant’s Current Report on Form 8-K filed with
the Commission on December 11, 2018).
3.7	Third
Amended and Restated Bylaws ( incorporated by reference to Exhibit 3.1 to the
Registrant’s Quarterly Report on Form 10-Q filed with the
Commission on September 9, 2015 ).
5.1	Opinion of K&L Gates, LLP.*
23.1	Consent of Independent Registered Public Accounting Firm, Cherry
Bekaert LLP.*
23.2	Consent of K&L Gates, LLP (Contained in Exhibit
5.1).
24.1	Power of Attorney (Contained on signature page).
99.1	Tenax Therapeutics, Inc. 2016 Stock Incentive Plan (incorporated by
reference to Exhibit 10.1 to the Registrant’s Quarterly
Report on Form 10-Q filed with the Commission on August 9,
2016).+
99.2	Amendment No. 1 to Tenax Therapeutics, Inc. 2016 Stock Incentive
Plan (incorporated by reference to Exhibit 10.1 to the
Registrant’s Quarterly Report on Form 10-Q filed with the
Commission on August 14, 2019).+
99.3	Amendment No. 2 to Tenax Therapeutics, Inc. 2016 Stock Incentive
Plan (incorporated by reference to Exhibit 10.1 to the
Registrant’s Quarterly Report on Form 10-Q filed with the
Commission on August 16, 2021)+
99.4	Plan for Employee Inducement Stock Option Grants*+
	* Filed Herewith + Management contract or compensatory plan or
arrangement

page break line

Item 9. Undertakings

(a)

The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) to reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

(iii) to include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in the registration statement;

provided , however , that Paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8 ( § 239.16b of this chapter), and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 ( 15 U.S.C. 78m or 78o(d) ) that are incorporated by reference in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration, by means of a post-effective amendment, any of the securities being registered which remain unsold at the termination of the offering.

(b)

The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c)

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrants, pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

page break

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized , in the Town of Morrisville, State of North Carolina, on September 2, 2021 .

TENAX THERAPEUTICS, INC.
By:	/s/ Michael B. Jebsen
	Michael B. Jebsen
	President and Chief Financial Officer

page break

KNOW ALL MEN BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Michael B. Jebsen his true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Name	Title	Date
/s/ Christopher T.
Giordano	Chief Executive Officer and Director	September 2, 2021
Christopher T. Giordano	(Principal
Executive Officer)
/s/ Michael B. Jebsen	Chief Financial Officer	September 2, 2021
Michael B. Jebsen	(Principal Financial Officer and Principal Accounting
Officer)
/s/ Stuart Rich	Chief Medical Officer and Director	September 2, 2021
Stuart Rich
/s/ Michael Davidson	Director	September 2, 2021
Michael Davidson
/s/ Steven Boyd	Director	September 2, 2021
Steven Boyd
/s/ James Mitchum	Director	September 2, 2021
James Mitchum
/s/ June Almenoff	Director	September 2, 2021
June Almenoff
/s/ Gerald Proehl	Director	September 2, 2021
Gerald Proehl
/s/ Declan Doogan	Director	September 2, 2021
Declan Doogan
/s/ Keith Maher	Director	September 2, 2021
Keith Maher

page break